Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Simon B. Zeichner, Stuart Herna, Aruna Mani, Tadeu Ambros, Alberto J. Montero, Reshma Mahtani, Eugene R. Ahn, Charles Vogel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Approximately 6 % of patients with breast cancer are diagnosed with de-novo distant metastases. We set out to look at two cohorts of patients seen at breast cancer-specific practices, compare the results to other reports and larger databases, and see how advances in treatment have impacted overall survival (OS). The records from a large breast cancer oncology private practice and a second data set from the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC) tumor database were, retrospectively, reviewed to identify patients with de-novo metastases. We included those patients identified to have metastatic disease within 3 months of diagnosis of a breast primary cancer. Patients diagnosed between 1996 and 2006 were chosen for our study population. The OS for the private practice was 41.0 months (46.0 for ER positive and 26.0 for ER negative) and 36.0 months for UM/SCCC (52 months for ER positive and 36 months for ER negative). ER negativity and CNS- or visceral-dominant disease were associated with a significantly worse prognosis within the private practice. Dominant site was associated with a significantly worse prognosis within the UM/SCCC database but with a trend also for ER negativity. Age and ethnicity did not contribute significantly to the survival of patients within either cohort. The median survival in both cohorts and most other reported series was larger than that seen in the surveillance, epidemiology, and end results program and the National Cancer Database. The median OS among patients with de-novo metastatic breast cancer treated within two breast-specific oncology practices was over 3 years, which appears better than larger, more inclusive databases and publications from earlier decades.

Original languageEnglish (US)
Pages (from-to)617-624
Number of pages8
JournalBreast Cancer Research and Treatment
Volume153
Issue number3
DOIs
StatePublished - Sep 10 2015

Fingerprint

Private Practice
Breast Neoplasms
Survival
Databases
Neoplasms
SEER Program
Neoplasm Metastasis
Publications
Breast
Population

Keywords

  • De-novo metastatic breast cancer
  • ER
  • HER2
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Survival of patients with de-novo metastatic breast cancer : analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. / Zeichner, Simon B.; Herna, Stuart; Mani, Aruna; Ambros, Tadeu; Montero, Alberto J.; Mahtani, Reshma; Ahn, Eugene R.; Vogel, Charles.

In: Breast Cancer Research and Treatment, Vol. 153, No. 3, 10.09.2015, p. 617-624.

Research output: Contribution to journalArticle

@article{c15cb52f35284d75a49ac09eaaf286ac,
title = "Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature",
abstract = "Approximately 6 {\%} of patients with breast cancer are diagnosed with de-novo distant metastases. We set out to look at two cohorts of patients seen at breast cancer-specific practices, compare the results to other reports and larger databases, and see how advances in treatment have impacted overall survival (OS). The records from a large breast cancer oncology private practice and a second data set from the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC) tumor database were, retrospectively, reviewed to identify patients with de-novo metastases. We included those patients identified to have metastatic disease within 3 months of diagnosis of a breast primary cancer. Patients diagnosed between 1996 and 2006 were chosen for our study population. The OS for the private practice was 41.0 months (46.0 for ER positive and 26.0 for ER negative) and 36.0 months for UM/SCCC (52 months for ER positive and 36 months for ER negative). ER negativity and CNS- or visceral-dominant disease were associated with a significantly worse prognosis within the private practice. Dominant site was associated with a significantly worse prognosis within the UM/SCCC database but with a trend also for ER negativity. Age and ethnicity did not contribute significantly to the survival of patients within either cohort. The median survival in both cohorts and most other reported series was larger than that seen in the surveillance, epidemiology, and end results program and the National Cancer Database. The median OS among patients with de-novo metastatic breast cancer treated within two breast-specific oncology practices was over 3 years, which appears better than larger, more inclusive databases and publications from earlier decades.",
keywords = "De-novo metastatic breast cancer, ER, HER2, Survival",
author = "Zeichner, {Simon B.} and Stuart Herna and Aruna Mani and Tadeu Ambros and Montero, {Alberto J.} and Reshma Mahtani and Ahn, {Eugene R.} and Charles Vogel",
year = "2015",
month = "9",
day = "10",
doi = "10.1007/s10549-015-3564-3",
language = "English (US)",
volume = "153",
pages = "617--624",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Survival of patients with de-novo metastatic breast cancer

T2 - analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

AU - Zeichner, Simon B.

AU - Herna, Stuart

AU - Mani, Aruna

AU - Ambros, Tadeu

AU - Montero, Alberto J.

AU - Mahtani, Reshma

AU - Ahn, Eugene R.

AU - Vogel, Charles

PY - 2015/9/10

Y1 - 2015/9/10

N2 - Approximately 6 % of patients with breast cancer are diagnosed with de-novo distant metastases. We set out to look at two cohorts of patients seen at breast cancer-specific practices, compare the results to other reports and larger databases, and see how advances in treatment have impacted overall survival (OS). The records from a large breast cancer oncology private practice and a second data set from the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC) tumor database were, retrospectively, reviewed to identify patients with de-novo metastases. We included those patients identified to have metastatic disease within 3 months of diagnosis of a breast primary cancer. Patients diagnosed between 1996 and 2006 were chosen for our study population. The OS for the private practice was 41.0 months (46.0 for ER positive and 26.0 for ER negative) and 36.0 months for UM/SCCC (52 months for ER positive and 36 months for ER negative). ER negativity and CNS- or visceral-dominant disease were associated with a significantly worse prognosis within the private practice. Dominant site was associated with a significantly worse prognosis within the UM/SCCC database but with a trend also for ER negativity. Age and ethnicity did not contribute significantly to the survival of patients within either cohort. The median survival in both cohorts and most other reported series was larger than that seen in the surveillance, epidemiology, and end results program and the National Cancer Database. The median OS among patients with de-novo metastatic breast cancer treated within two breast-specific oncology practices was over 3 years, which appears better than larger, more inclusive databases and publications from earlier decades.

AB - Approximately 6 % of patients with breast cancer are diagnosed with de-novo distant metastases. We set out to look at two cohorts of patients seen at breast cancer-specific practices, compare the results to other reports and larger databases, and see how advances in treatment have impacted overall survival (OS). The records from a large breast cancer oncology private practice and a second data set from the University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC) tumor database were, retrospectively, reviewed to identify patients with de-novo metastases. We included those patients identified to have metastatic disease within 3 months of diagnosis of a breast primary cancer. Patients diagnosed between 1996 and 2006 were chosen for our study population. The OS for the private practice was 41.0 months (46.0 for ER positive and 26.0 for ER negative) and 36.0 months for UM/SCCC (52 months for ER positive and 36 months for ER negative). ER negativity and CNS- or visceral-dominant disease were associated with a significantly worse prognosis within the private practice. Dominant site was associated with a significantly worse prognosis within the UM/SCCC database but with a trend also for ER negativity. Age and ethnicity did not contribute significantly to the survival of patients within either cohort. The median survival in both cohorts and most other reported series was larger than that seen in the surveillance, epidemiology, and end results program and the National Cancer Database. The median OS among patients with de-novo metastatic breast cancer treated within two breast-specific oncology practices was over 3 years, which appears better than larger, more inclusive databases and publications from earlier decades.

KW - De-novo metastatic breast cancer

KW - ER

KW - HER2

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84942988479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942988479&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3564-3

DO - 10.1007/s10549-015-3564-3

M3 - Article

C2 - 26358708

AN - SCOPUS:84942988479

VL - 153

SP - 617

EP - 624

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -